Mobilization of hematopoietic progenitor cells from allogeneic healthy donors using a new biosimilar G-CSF (Zarzio®).

摘要: Peripheral blood progenitor cells (PBPCs) have become the major source of hematopoietic for allogeneic transplantation. In February 2008, Zarzio® was approved by European Medicine Agency PBPCs mobilization, but this authorization not based in trials analyzing safety and efficacy mobilization. Since August 2011, has been used at our institution total 36 healthy family donors underwent 18 with Neupogen® Zarzio®. Donor characteristics were equivalent between groups, no severe adverse effects registered group. The number CD34 collected/Kg recipient body weight 6.7 × 106 (3.8–11.1) group versus 8.4 (5.6–16.6) (P = 0.04). We collected minimal target cell dose (2 106/kg) all from each significant differences found collection optimal (5 although 3/18 (16.6%) that received failed to mobilize compared 0% A 35 patients proceeded transplantation (17 respectively). Platelet neutrophil median time engraftment comparable two groups. Our retrospective study supports conclusion mobilization is safe perhaps as effective reference Neupogen. However, more prospective are required definitively asses G-CSF biosimilars donors. J. Clin. Apheresis 31:48–52, 2016. © 2015 Wiley Periodicals, Inc.